Bio-rad Laboratories Stock Earnings Reports

Bio‑Rad reported Q1 2026 net sales of ~$592M, up 1.1% reported but down ~4.2% on a currency‑neutral basis. Performance was weighed down by a significant revenue and logistics disruption tied to the conflict in the Middle East (an ~ $11M Q1 impact and ongoing headwind for 2026). Life Science revenues were essentially flat (ddPCR instruments +24% while consumables were softer), with academic funding weakness and a modest biopharma recovery expected. Clinical Diagnostics grew ~1.9% reported but declined on a currency‑neutral basis, with quality systems and immunohematology resilient outside the affected region. Non‑GAAP gross margin guidance is 53–54% and non‑GAAP operating margin 10–12% for 2026; full‑year currency‑neutral revenue guidance was revised to -3% to +0.5%. Q1 non‑GAAP net income was $51M ($1.89 EPS) vs. $71M a year ago; reported results included a large unrealized Sartorius equity movement driving a reported net loss. Cash/short‑term investments were $1.565B, free cash flow guidance lowered to ~$290M–$340M, and the company remains opportunistic on buybacks (≈$237M capacity remaining). Management emphasized operational actions (supply chain rationalization, localized manufacturing “In China, For China”), portfolio prioritization (R&D focus, 99% of digital PCR assays on QX700), and a disciplined, targeted M&A approach focusing on revenue‑generating targets in the $100M–$500M range. Near term, management will pursue discretionary spend reduction and broader structural efficiency measures while awaiting resolution of geopolitical headwinds.